Ultrasound guided corticosteroid injection for plantar fasciitis: Randomised controlled trial
journal contributionposted on 27.05.2021, 04:06 by AM McMillan, Karl Landorf, Mark Gilheany, Adam Bird, AD Morrow, Hylton Menz
Objective: To investigate the effectiveness of ultrasound guided corticosteroid injection in the treatment of plantar fasciitis. Design: Randomised, investigator and participant blinded, placebo controlled trial. Setting: University clinic in Melbourne, Australia. Participants: 82 people with a clinical and ultrasound diagnosis of plantar fasciitis unrelated to systemic inflammatory disease. Interventions: Participants were randomly allocated to ultrasound guided injection of the plantar fascia with either 1 mL of 4 mg/mL dexamethasone sodium phosphate (experimental group) or 1 mL normal saline (placebo). Before injection the participants were given an ultrasound guided posterior tibial nerve block with 2% lidocaine (lignocaine). Main outcome measures: Primary outcomes were pain, as measured by the foot health status questionnaire (0-100 point scale), and plantar fascia thickness, measured by ultrasound at 4, 8, and 12 weeks. Results: Reduction in pain at four weeks favoured the dexamethasone group by 10.9 points (95% confidence interval 1.4 to 20.4, P=0.03). Between group differences for pain scores at eight and 12 weeks were not statistically significant. Plantar fascia thickness measured at four weeks favoured the dexamethasone group by -0.35 mm (95% confidence interval -0.67 to -0.03, P=0.03). At eight and 12 weeks, between group differences for plantar fascia thickness also favoured dexamethasone, at -0.39 mm (-0.73 to -0.05, P=0.02) and -0.43 mm (-0.85 to -0.01, P=0.04), respectively. The number needed to treat with dexamethasone for one successful outcome for pain at four weeks was 2.93 (95% confidence interval 2.76 to 3.12). There were no reported adverse events associated with the intervention. Conclusion: A single ultrasound guided dexamethasone injection is a safe and effective short term treatment for plantar fasciitis. It provides greater pain relief than placebo at four weeks and reduces abnormal swelling of the plantar fascia for up to three months. However, clinicians offering this treatment should also note that significant pain relief did not continue beyond four weeks. Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000239066.
This study was funded by the Australian Podiatry Education and Research Foundation. AMcM has received an Australian Postgraduate Award scholarship. HBM is a National Health and Medical Research Council senior research fellow (ID: 1020925). Briggate Medical (Victoria, Australia) donated medical consumables used in the trial.
Article NumberARTN e3260
PublisherBMJ PUBLISHING GROUP
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineMedicine, General & InternalGeneral & Internal MedicineHEEL PAINSTEROID INJECTIONPATELLAR TENDONFOOTHEALTHPREVALENCEINJURIESCAREHumansFasciitis, PlantarPainDexamethasoneGlucocorticoidsUltrasonography, InterventionalTreatment OutcomeInjectionsCohort StudiesDouble-Blind MethodAdultMiddle AgedFemaleMale